President and CEO, Christopher J. Burns, Ph.D., will present at the First-Time Disclosure of Clinical Candidates Oral Symposium on March 21, 2018 at 3:15pm CT

Malvern, PA, March 19, 2018Venatorx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present its lead clinical antibacterial candidate, VNRX-5133, during the First-Time Disclosure of Clinical Candidates Symposium at the American Chemical Society (ACS) National Meeting on Wednesday, March 21, 2018 at 3:15pm CT in the La Nouvelle Orleans Ballrooms A/B at the Ernest N. Morial Convention Center in New Orleans, LA. The oral presentation is entitled, “Discovery of VNRX-5133: A broad-spectrum serine- and metallo-beta-lactamase inhibitor (BLI) for carbapenem-resistant bacterial infections (“superbugs”).”

VNRX-5133 is a new-generation BLI with unique broad-spectrum activity, covering both serine- and metallo-beta-lactamases. Venatorx is developing VNRX-5133 in a fixed combination with the 4th generation cephalosporin Cefepime to provide a best-in-class treatment option for infections caused by multi-drug resistant (MDR) gram-negative bacteria, including: carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa; suspected polymicrobial infections caused by both gram-negative and gram-positive pathogens; and bioterror pathogens such as Burkholderia spp. and Salmonella spp.

This project has been funded in whole or in part with Federal funds from the National Institute for Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300019C, and Wellcome Trust under Award No. 360G-Wellcome-101999/Z/13/Z.

About Venatorx Pharmaceuticals, Inc.

Led by a world-class team of pharmaceutical veterans, Venatorx is a private pharmaceutical company that is developing a new wave of antibiotic products to combat the increasing threat of carbapenem antibiotic resistance. Venatorx’s lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four major classes of beta-lactamases. VNRX-5133, in combination with cefepime, has completed early clinical studies and plans to start Phase 3 pivotal trials in mid-2018. In addition, Venatorx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, and a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance. For more information, please visit